An NRG Oncology SPPORT trial analysis found that Luminal B prostate tumors identified by the PAM50 genomic classifier predicted a much larger benefit from adding short-term hormone therapy to salvage ...
Patients with intermediate-risk prostate cancer who can safely forgo androgen deprivation therapy (ADT) may be spared its quality-of-life effects.
The companies will collaborate with AstraZeneca to advance local lab testing for a prostate cancer genomic instability ...
A comprehensive review shows circulating tumour DNA offers powerful prognostic insight across all major mCRPC treatments, but ...
AI-based research identifies ZNF268 as a potential marker of prostate cancer progression, raising hopes for more accurate ...
"Is cancer genetic testing something that is passed down to family members?" Have you ever felt anxious about that?By reading ...
HT Health Talk: Prostate cancer is common but often silent. Should you get checked earlier if your father or brother had it?
Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer / A. Keith Stewart., Alan H. Bryce, Alan L.
Myriad Genetics, SOPHiA GENETICS and AstraZeneca are collaborating to advance Myriad’s prostate cancer genomic instability ...
SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new ...
It’s easy to assume having a mom or grandmother with breast cancer doesn’t impact your own health, but that’s not the case.
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) today announce a collaboration to advance new prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results